Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. (24th July 2021)

• Record Type: Journal Article
• Authors: Ishikawa, Tomohiko; Takahashi, Toshinari; Taniguchi, Tetsuya; Hosoya, Tatsuo
• Is Part Of: Expert opinion on pharmacotherapy. Volume 22:Number 11(2021)
• Page Start: 1397
• Page End: 1406
• Publication Date: 2021-07-24
• Subjects: dotinurad -- gout -- hyperuricemia -- selective urate reabsorption inhibitor (SURI) -- urate-lowering therapy -- URAT1; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2021.1918102
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Gout is an inflammatory disease triggered by deposition of urate crystals secondary to longstanding hyperuricemia, and its management implies both the treatment of flares and management of hyperuricemia. Dotinurad is a selective urate reabsorption inhibitor (SURI), potently inhibits urate transporter 1 in the apical surface of renal proximal tubular cells, and has been approved for the treatment of gout and hyperuricemia in Japan. Areas covered: This overview of dotinurad covers nonclinical and clinical pharmacology studies in special populations and its efficacy and safety in Japanese hyperuricemic patients with and without gout. Expert opinion: Dotinurad, as an SURI, is expected to inhibit urate reabsorption more effectively than conventional urate-lowering agents. It is noninferior to benzbromarone or febuxostat in reducing serum urate levels in hyperuricemic patients with or without gout. Its efficacy is not attenuated in patients with mild to moderate renal impairment or with hepatic impairment. At a maintenance dose of 2 or 4 mg once daily, most patients achieved the target serum urate level of ≤6 mg/dL in a long-term study. No findings that raised safety concerns, including liver injury, were identified. Dotinurad is expected to be a new therapeutic option in hyperuricemic patients with and without gout.